Britain's MHRA authorised Eli Lilly's oral weight-loss pill Foundayo for weight management and type 2 diabetes, the first European approval for both indications. The once-daily pill, which carries no food or water restrictions, launches in the UK later this month via private prescription, priced…
Eli Lilly's oral weight-loss pill Foundayo has received its first European approval. Britain's Medicines and Healthcare products Regulatory Agency MHRA authorised the treatment for weight management and type 2 diabetes on Monday, making the United Kingdom the first country in Europe to approve the drug for both weight management and type 2 diabetes. Foundayo becomes the second oral GLP-1 pill cleared in the UK, after Novo Nordisk's Wegovy pill was approved in June.
Eli Lilly expects to launch Foundayo in the UK later this month through private prescription, an Eli Lilly spokesman said. The spokesman, who was not identified by name, said the company would price the pill below Mounjaro 's UK list price of £330 for a month's supply, without disclosing a precise figure. The medicine is approved in the UK but is not currently available through the NHS.
The decision inserts a second oral competitor into a weight-loss market dominated by injectable therapies from Eli Lilly and Novo Nordisk and now expanding into oral treatments. The two oral pills differ at the level of daily use. Foundayo is taken once daily with no food or water restrictions. The Wegovy pill must be taken on an empty stomach with a small amount of water, followed by a 30-minute wait before food, beverages, or other medications. The leading injectables, by contrast, are dosed once weekly. That contrast, between a daily tablet and a weekly injection and between two daily tablets with different fasting requirements, frames the clinical choice now emerging in Britain.
The MHRA's decision marks the first time a European regulator has cleared Foundayo for both weight management and type 2 diabetes in a single licence. The agency's announcement carried a direct caveat for patients and prescribers: "Whilst this tablet is approved for use in the UK, it is not available currently via the NHS."
Marketing authorisation and health service access are separate steps. The MHRA licence establishes that the medicine meets the UK's standards for safety, quality, and efficacy for its granted indications. Whether the NHS will fund Foundayo, and under what conditions, depends on separate appraisal and commissioning decisions that have not been announced. In England, a new medicine typically reaches NHS patients only after a technology appraisal by the National Institute for Health and Care Excellence NICE that weighs clinical benefit against cost; the devolved UK health systems run their own processes. None of those appraisals has been announced for Foundayo. For now, the only route to the medicine in the UK is the private prescription channel, where patients bear the cost of the medicine and any private consultation.
Pricing will position the drug at a discount to the established injectable. The company has not disclosed the exact UK price, saying only that it will be lower than the list price of its injectable Mounjaro. The reference point matters because the UK private weight-loss market has matured around a set of known monthly costs, and because oral formulations carry a different manufacturing and supply profile from injectables, so cost structures are not directly comparable. A list price below £330 signals that Lilly intends the oral product to compete partly on price, not only on convenience, but the final out-of-pocket figure remains undisclosed.
The private channel also shapes who gets the drug first. Private weight-management prescribing in the UK typically runs through dedicated clinics and online services that require a private consultation rather than a GP referral, so access in the first months will be limited to patients who can pay for the consultation, the drug, and follow-up visits on top of the undisclosed list price. That makes the effective monthly cost higher than the drug price alone, and it creates a two-speed introduction for two chronic conditions whose burden in the UK falls disproportionately on people with lower incomes. The pattern is familiar from the earlier rollout of the injectable GLP-1 products, which also reached NHS patients only after appraisal while private clinics offered them immediately.
The UK action is one of several regulatory decisions now moving at different speeds across Europe. Foundayo is authorised in Britain and remains under review in the European Union. Novo Nordisk's Wegovy pill, which already holds UK approval, has received a positive recommendation from the European Medicines Agency EMA , but a final approval decision from the European Commission is pending.
The split reflects the UK's independent medicines regime. Since leaving the EU, Britain assesses medicines through the MHRA rather than through the EMA and the European Commission, so approval timelines for the same product can diverge. The EMA's positive opinion is a step in the EU's centralised procedure, under which the Commission normally issues a single decision binding across member states, but that decision is a separate legal act and its timing is not fixed by the recommendation. The practical consequence is a staggered rollout: UK patients can access both oral GLP-1 pills through private prescriptions while European patients wait on decisions that could take a different shape or pace.
The ordering also matters commercially. Novo Nordisk will have held the UK oral market alone for several months before Lilly's product launches. In the EU, the sequence is different: the Wegovy pill is further along in the review process, while Foundayo's assessment is at an earlier stage. In the US, by contrast, both products are already on the market. Regulators and payers on both sides of the Atlantic will be watching the UK experience, because it will produce the first European real-world evidence on how the two oral formulations perform outside clinical trials.
The divergence also creates a practical information problem for prescribers. British clinicians will be asked to explain why two products in the same class arrived by different routes, and why one comes with a food restriction and the other does not. The two summaries of product characteristics will sit side by side in UK prescribing systems. For the companies, the UK becomes a test market in which the Wegovy pill has first-mover familiarity while Foundayo enters with a convenience claim and a lower list price. Which variable, sequence or convenience, drives early prescribing will be measurable within months from private prescription volumes. The UK's head start also means European regulators will finalise their decisions with early UK prescribing data, including discontinuation patterns, available to them.
The scientific hurdle in any oral GLP-1 product is the gut itself. GLP-1 is a peptide hormone released from intestinal L-cells after meals, and it acts through GLP-1 receptors on pancreatic beta cells, the digestive tract, and the brain to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. That pharmacology is well established. Delivering the same peptide orally is not.
The physiology explains both the therapeutic value and the safety profile of the class. When glucose is absorbed from a meal, GLP-1 amplifies the insulin response, and the effect is glucose dependent: at fasting glucose levels the hormone does little to insulin secretion, which is why GLP-1-based medicines carry a low intrinsic risk of hypoglycaemia when used without sulfonylureas or insulin. The hormone also suppresses glucagon release from pancreatic alpha cells and slows the passage of food through the stomach, a combination that dampens post-meal glucose spikes and contributes to the sense of fullness that underlies weight loss. In the brain, GLP-1 receptor signalling in the hypothalamus and brainstem modulates appetite and satiety. The native peptide, however, is a poor medicine. It is degraded within minutes by the enzyme dipeptidyl peptidase-4 , so the products on the market are engineered molecules designed to resist that cleavage: longer-acting analogues of the natural hormone rather than the hormone itself. The class also carries a well-documented gastrointestinal cost. Nausea, vomiting, and diarrhoea are dose-limiting side effects, particularly when treatment starts or escalates, and they are a common reason patients stop. Those effects matter for an oral product, because GI discomfort and a complex dosing routine feed the same persistence problem.
Peptides are poor oral drugs by nature. The gastrointestinal tract is built to dismantle them. Gastric acid denatures the molecule, digestive proteases and peptidases cleave it into fragments, and the intestinal epithelium presents a low-permeability barrier to molecules of this size and polarity. A swallowed peptide must survive those barriers in sufficient quantity, and with acceptable consistency between doses, before enough reaches the circulation. Getting it across requires formulation technology: protective coatings that resist acid, protease inhibitors that slow enzymatic attack, and absorption enhancers that transiently loosen the epithelial barrier so the peptide can pass. Each strategy carries a cost. Enhancers that open the gut wall to a large peptide can also increase uptake of other substances present in the gut at the same time, which is why drug-interaction windows are a central question in oral peptide development. A formulation that depends on a narrow pH window, or that must reach a specific site in the intestine before the enhancer wears off, is vulnerable to variability from anything that changes transit time, acid secretion, or enzyme output.
The quantitative reality compounds the problem. Oral bioavailability for peptide drugs is typically low, often in the single digits: a small and variable fraction of the swallowed dose reaches the circulation, and the rest is destroyed or excreted. That does not make the drug ineffective, provided the absorbed fraction is reproducible, but reproducibility is exactly what food threatens. The gut's barriers are not a fixed wall; they are conditions that change with every meal. Acid secretion rises and falls, pancreatic enzymes are released in response to food, gastric emptying slows as the stomach fills, and the volume of contents a tablet must pass through enlarges. A drug with a narrow absorption window, an enhancer sensitive to pH or bile, or gastric emptying that determines its transit will deliver a different dose after a high-fat breakfast than after an overnight fast. The fasting instruction is therefore not a convenience detail. It is an attempt to hold the variables constant so that each dose behaves like the last.
The two pills now approved in the UK illustrate what different formulation choices mean for the patient. The Wegovy pill depends on strict dosing conditions: empty stomach, small amount of water, and a 30-minute wait before any food, beverages, or other medications. Food changes the gastric environment in several ways at once: it stimulates acid and pancreatic enzyme secretion, it slows gastric emptying, and it enlarges the volume of gastric contents a tablet must pass through. A drug whose absorption is sensitive to those variables will behave differently in the fed and fasted states, and the fasting requirement is a way of holding them constant. Foundayo carries no such restrictions. The absence of a food or water requirement implies a formulation with a wider absorption window and less sensitivity to pH and gastric contents. That is a meaningful convenience claim, but a dosing instruction is not the same as proof that absorption is food-independent; the…
Peptides referenced: Semaglutide, Tirzepatide, Glucagon, GLP-1.
Related reading: Federal pilot caps Medicare GLP-1 weight-loss copays at $50, Yale study: hunger neurons help GLP-1 drugs sustain fat loss, MHRA Yellow Card data link GLP-1 drugs to 153 fatality reports, Tirzepatide tied to 32% lower MACE risk in real-world diabetes cohort.